Erythropoietin treatment in patients with acute myocardial infarction: A meta-analysis of randomized controlled trials

American Heart Journal

Volumn 164, Issue 5, 2012, Pages

  Gao, Dengfeng ^a   Ning, Ning ^a   Niu, Xiaolin ^a   Dang, Yinhu ^a   Dong, Xin ^a   Wei, Jin ^a   Zhu, Canzhan ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE MB; ERYTHROPOIETIN; PLACEBO;

ACUTE HEART INFARCTION; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MAGNETIC RESONANCE; COCHRANE LIBRARY; DRUG MEGADOSE; DRUG SAFETY; EMBASE; HEART FAILURE; HEART FUNCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HUMAN; IMAGE ANALYSIS; LOW DRUG DOSE; MEDLINE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RISK ASSESSMENT; SINGLE DRUG DOSE; STENT THROMBOSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 84868608614     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2012.07.031     Document Type: Article

References (45)

1. V.L. Roger, A.S. Go, and D.M. Lloyd-Jones Heart disease and stroke statistics-2011 update: a report from the American Heart Association Circulation 123 4 2011 e18 209
2. K.A. Fox, P.G. Steg, and K.A. Eagle Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006 JAMA 297 17 2007 1892 1900
3. W.E. Boden, K. Eagle, and C.B. Granger Reperfusion strategies in acute ST-segment elevation myocardial infarction: a comprehensive review of contemporary management options J Am Coll Cardiol 50 10 2007 917 929
4. G. Esposito, S. Dellegrottaglie, and M. Chiariello The extent of irreversible myocardial damage and the potential for left ventricular repair after primary percutaneous coronary intervention Am Heart J 160 6 Suppl 2010 S4 10
5. J.J. Gajarsa, and R.A. Kloner Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities Heart Fail Rev 16 1 2011 13 21
6. A. Kashani, and R.P. Giugliano Management of ST-elevation myocardial infarction: an update on pharmacoinvasive recanalization Am J Cardiovasc Drugs 8 3 2008 187 197
7. F. Saia, F. Grigioni, and A. Marzocchi Management of acute left ventricular dysfunction after primary percutaneous coronary intervention for ST elevation acute myocardial infarction Am Heart J 160 6 Suppl 2010 S16 S21
8. D.H. Henry, P. Bowers, and M.T. Romano Epoetin alfa. Clinical evolution of a pleiotropic cytokine Arch Intern Med 164 3 2004 262 276
9. W.P. Ruifrok, R.A. de Boer, and B.D. Westenbrink Erythropoietin in cardiac disease: new features of an old drug Eur J Pharmacol 585 2-3 2008 270 277
10. A. Hirata, T. Minamino, and H. Asanuma Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs J Am Coll Cardiol 48 1 2006 176 184
11. P. van der Meer, E. Lipsic, and R.H. Henning Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury Eur J Heart Fail 6 7 2004 853 859
12. C. Moon, M. Krawczyk, and D. Ahn Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats Proc Natl Acad Sci U S A 100 20 2003 11612 11617
13. P. van der Meer, E. Lipsic, and R.H. Henning Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction J Am Coll Cardiol 46 1 2005 125 133
14. S. Chateauvieux, C. Grigorakaki, and F. Morceau Erythropoietin, erythropoiesis and beyond Biochem Pharmacol 82 10 2011 1291 1303
15. A.S. Binbrek, N.S. Rao, and N. Al Khaja Erythropoietin to augment myocardial salvage induced by coronary thrombolysis in patients with ST segment elevation acute myocardial infarction Am J Cardiol 104 8 2009 1035 1040
16. M. Ferrario, E. Arbustini, and M. Massa High-dose erythropoietin in patients with acute myocardial infarction: a pilot, randomised, placebo-controlled study Int J Cardiol 147 1 2011 124 131
17. A. Liem, A.P. van de Woestijne, and E. Bruijns Effect of EPO administration on myocardial infarct size in patients with non-STE acute coronary syndromes; results from a pilot study Int J Cardiol 131 2 2009 285 287
18. E. Lipsic, P. van der Meer, and A.A. Voors A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study Cardiovasc Drugs Ther 20 2 2006 135 141
19. S.S. Najjar, S.V. Rao, and C. Melloni Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial JAMA 305 18 2011 1863 1872
20. I. Ott, S. Schulz, and J. Mehilli Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial Circ Cardiovasc Interv 3 5 2010 408 413
21. T. Ozawa, K. Toba, and H. Suzuki Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction - randomized controlled pilot trial of EPO/AMI-1 study Circ J 74 7 2010 1415 1423
22. J.W. Suh, W.Y. Chung, and Y.S. Kim The effect of intravenous administration of erythropoietin on the infarct size in primary percutaneous coronary intervention Int J Cardiol 149 2 2011 216 220
23. Y.D. Tang, F. Hasan, and F.J. Giordano Effects of recombinant human erythropoietin on platelet activation in acute myocardial infarction: results of a double-blind, placebo-controlled, randomized trial Am Heart J 158 6 2009 941 947
24. N. Taniguchi, T. Nakamura, and T. Sawada Erythropoietin prevention trial of coronary restenosis and cardiac remodeling after ST-elevated acute myocardial infarction (EPOC-AMI): a pilot, randomized, placebo-controlled study Circ J 74 11 2010 2365 2371
25. A.A. Voors, A.M. Belonje, and F. Zijlstra A single dose of erythropoietin in ST-elevation myocardial infarction Eur Heart J 31 21 2010 2593 2600
26. D. Moher, A. Liberati, and J. Tetzlaff Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement BMJ 339 2009 b2535
27. M. van Tulder, A. Furlan, and C. Bombardier Updated method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group Spine (Phila Pa 1976) 28 12 2003 1290 1299
28. R.B. Haynes, K.A. McKibbon, and N.L. Wilczynski Optimal search strategies for retrieving scientifically strong studies of treatment from Medline: analytical survey BMJ 330 7501 2005 1179
29. S.S. Wong, N.L. Wilczynski, and R.B. Haynes Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE J Med Libr Assoc 94 1 2006 41 47
30. S. Hopewell, S. McDonald, and M. Clarke Grey literature in meta-analyses of randomized trials of health care interventions Cochrane Database Syst Rev 2 2007 MR000010
31. A.R. Jadad, R.A. Moore, and D. Carroll Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1 1996 1 12
32. J.P. Higgins, D.G. Altman, and P.C. Gotzsche The Cochrane Collaboration's tool for assessing risk of bias in randomised trials BMJ 343 2011 d5928
33. A.J. Ludman, D.M. Yellon, and J. Hasleton Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial Heart 97 19 2011 1560 1565
34. F. Prunier, L. Biere, and M. Gilard Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the erythropoietin in myocardial infarction trial Am Heart J 163 2 2012 200 207e1
35. V. Mastromarino, M. Volpe, and M.B. Musumeci Erythropoietin and the heart: facts and perspectives Clin Sci (Lond) 120 2 2011 51 63
36. S. Brunner, J. Winogradow, and B.C. Huber Erythropoietin administration after myocardial infarction in mice attenuates ischemic cardiomyopathy associated with enhanced homing of bone marrow-derived progenitor cells via the CXCR-4/SDF-1 axis FASEB J 23 2 2009 351 361
37. I. Ben-Dor, B. Hardy, and S. Fuchs Repeated low-dose of erythropoietin is associated with improved left ventricular function in rat acute myocardial infarction model Cardiovasc Drugs Ther 21 5 2007 339 346
38. S.L. Hale, C. Sesti, and R.A. Kloner Administration of erythropoietin fails to improve long-term healing or cardiac function after myocardial infarction in the rat J Cardiovasc Pharmacol 46 2 2005 211 215
39. A. Hirata, T. Minamino, and H. Asanuma Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts Cardiovasc Drugs Ther 19 1 2005 33 40
40. H. Kobayashi, T. Miura, and H. Ishida Limitation of infarct size by erythropoietin is associated with translocation of Akt to the mitochondria after reperfusion Clin Exp Pharmacol Physiol 35 7 2008 812 819
41. F.D. Olea, G. Vera Janavel, and A. De Lorenzi High-dose erythropoietin has no long-term protective effects in sheep with reperfused myocardial infarction J Cardiovasc Pharmacol 47 6 2006 736 741
42. J. Kristensen, M. Maeng, and M. Rehling Lack of acute cardioprotective effect from preischaemic erythropoietin administration in a porcine coronary occlusion model Clin Physiol Funct Imaging 25 5 2005 305 310
43. M.A. Pfeffer, E.A. Burdmann, and C.Y. Chen A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease N Engl J Med 361 21 2009 2019 2032
44. E.F. Unger, A.M. Thompson, and M.J. Blank Erythropoiesis-stimulating agents - time for a reevaluation N Engl J Med 362 3 2010 189 192
45. P. Widimsky, W. Wijns, and J. Fajadet Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries Eur Heart J 31 8 2010 943 957